Johnson & Johnson Positioned for Growth on Multiple MedTech and Immunology Catalysts, RBC Says

MT Newswires Live12-12

Johnson & Johnson (JNJ) is positioned for upside heading into 2026 as multiple medtech and immunology catalysts support the company's growth outlook, RBC Capital Markets said in a note Thursday.

RBC said Johnson & Johnson's top line target to "exceed 5%" growth in 2026 is a base case and that the company is positioned towards the upper end of between 5% to 7%.

The firm also flagged the planned separation of its orthopedics business as a meaningful earnings contributor, estimating about 75 basis points of sales and margin accretion as a base case post separation at the end of 2027.

RBC said the combination of a disciplined capital allocation strategy, pipeline momentum, and strong free cash flow puts the company "on a path to deliver competitive growth."

RBC reiterated its outperform rating and raised its price target to $230 from $209.

Price: 210.38, Change: +3.84, Percent Change: +1.86

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment